Dorzolamide and timolol saves retinal ganglion cells in glaucomatous adult rats

Journal of Ocular Pharmacology and Therapeutics

Volumn 21, Issue 6, 2005, Pages 454-462

  Sarup, Vimal ^a   McEwan, Gavin C ^a   Thompson, Carl ^a   Patil, Kiran A ^a   Sharma, Sansar C ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEPROMAZINE MALEATE; BACITRACIN; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; EYE DROPS; FLUOROGOLD; KETAMINE; XYLAZINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DENSITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; GLAUCOMA; INTRAOCULAR PRESSURE; NONHUMAN; RAT; RETINA GANGLION CELL; VEIN OCCLUSION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CELL COUNT; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; FEMALE; GLAUCOMA; INTRAOCULAR PRESSURE; PILOT PROJECTS; RATS; RATS, WISTAR; RETINAL GANGLION CELLS; SULFONAMIDES; THIOPHENES; TIME FACTORS; TIMOLOL;

EID: 30544436246     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2005.21.454     Document Type: Article

References (27)

1. Garcia-Valenzuela, E., Shareef, S., Walsh, J., et al. Programmed cell death of retinal ganglion cells during experimental glaucoma. Exp. Eye Res 61:33-44, 1995.
2. Laquis, S., Chaudhary, P., and Sharma, S.C. The patterns of retinal ganglion cell death in hypertensive eyes. Brain Res, 784(1-2):100-104, 1998.
3. Quigley, H.A., Nickells, R.W., Kerrigan, L.A. et al. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest. Ophthalmol. Vis. Sci. 36:774-786, 1995.
4. Chaudhary, P., Ahmed, F., and Sharma, S.C. MK801-a neuroprotectant in rat hypertensive eyes. Brain Res. 792(1):154-158, 1998.
5. Hegazy, K.A., Dunn, M.W., and Sharma, S.C. Functional human heme oxygenase has a neuroprotective effect on adult rat ganglion cells after pressure-induced ischemia. Neuroreport 11:1185-1189, 2000.
6. Ko, M.L., Hu, D.N., Ritch, R., et al. The combined effect of brain-derived neurotrophic factor and a free radical scavenger in experimental glaucoma. Invest. Ophthalmol. Vis. Sci. 41:2967-2971, 2000.
7. Neufeld, A.H., Sawada, A., and Becker, B. Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc. Natl. Acad. Sci. U.S.A. 96(17):9944-9948, 1999.
8. Bacharach, J., Delgado, M.F., and Iwach, A.G. Comparison of the efficacy of the fixed-combination timolol/dorzolamide versus concomitant administration of timolol and dorzolamide. J. Ocul. Pharmacol. Ther. 19:93-96, 2003.
9. Harris, A., Arend, O., Chung, H.S., et al. A comparative study of betaxolol and dorzolamide effect on ocular circulation in normal-tension glaucoma patients. Ophthalmology 107:430-434, 2000.
10. Sugrue, M.F. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog. Retin. Eye Res. 19(1):87-112, 2000.
11. Maren, T.H., Conroy, C.W., Wynns, G.C., et al. Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor. J. Ocul. Pharmacol. Ther. 13:23-30, 1997.
12. Tan, A.Y., LeVatte, T.L., Archibald, M.L., et al. Timolol concentrations in rat ocular tissues and plasma after topical and intraperitoneal dosing. J. Glaucoma 11(2):134-142, 2002.
13. Goto, W., Ota, T., Morikawa, N., et al. Protective effects of timolol against the neuronal damage induced by glutamate and ischemia in the rat retina. Brain Res. 958(1):10-19, 2002.
14. Melena, J., Stanton, D., and Osborne, N.N. Comparative effects of antiglaucoma drugs on voltage-dependent calcium channels. Graefes' Arch. Clin. Exp. Ophthalmol. 239(7):522-530, 2001.
15. Wood, J.P., Schmidt, K.G., Melena, J., et al. The beta-adrenoceptor antagonists metipranolol and timolol are retinal neuroprotectants: Comparison with betaxolol. Exp. Eye Res. 76(4):505-516, 2003.
16. Schuettauf, F., Quinto, K., Naskar, R., et al. Effects of antiglaucoma medications on ganglion cell survival: The DBA/2J mouse model. Vision Res. 42(20):2333-2337, 2002.
17. Sawada, A., and Neufeld, A.H. Confirmation of the rat model of chronic, moderately elevated intraocular pressure. Exp. Eye Res. 69(5)525-531, 1999.
18. Shareef, S.R., Garcia-Valenzuela, E., Salierno, A., et al. Chronic ocular hypertension following episcleral venous occlusion in rats. Exp. Eye Res. 61(3):379-382, 1995.
19. Mittag, T.W., Danias, J., Pohorenec, G., Yuan, H.M., Burakgazi, E., Chalmers-Redman, R., et al. Retinal damage after 3 to 4 months of elevated intraocular pressure in a rat glaucoma model. Invest Ophthalmol Vis Sci 2000;41(11):3451-3459.
20. Pang, I.H., Wang, W.H., and Clark, A.F. Acute effects of glaucoma medications on rat intraocular pressure. Exp. Eye Res. 80(2):207-214, 2006.
21. Seki, M., Tanaka, T., Matsuda, H., et al. Topically administered timolol and dorzolamide reduce intraocular pressure and protect retinal ganglion cells in a rat experimental glaucoma model. Br. J. Ophthalmol. 89(4):504-507, 2005.
22. Wilson, M.R., and Martone, J.F. Epidemiology of chronic open angle glaucoma. In: Ritch, R., Shields, M.B., and Krupin, T. eds. The Glaucomas. St. Louis, MO: Mosby, 1996:753-768.
23. Brubaker, R.F. Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture. Am. J. Ophthalmol. 121(5):473-483, 1996.
24. Weinreb, R.N., and Levin, L.A. Is neuroprotection a viable therapy for glaucoma? Arch. Ophthalmol. 117(11):1540-1544, 1999.
25. Schuettauf, F., Quinto, K., Naskar, R., et al. Effects of antiglaucoma medications on ganglion cell survival: The DBA/2J mouse model. Vision Res. 42(20):2333-2337, 2002.
26. Hutzelmann, J., Owens, S., Shedden, A., et al. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: A clinical equivalence study. International Clinical Equivalence Study Group. Br. J. Ophthalmol. 82(11):1249-1253, 1998.
27. Francis, B.A., Du, L.T., Berke, S., et al. Comparing the fixed combination dorzolamide-timolol (Cosopt) to concomitant administration of 2% dorzolamide (Trusopt. and 0.5% timolol-a randomized, controlled trial and a replacement study. J. Clin. Pharm. Ther. 29(4):375-380, 2004.